Latest:
BiTE Platform and the Evolution Toward Off-The-Shelf Immuno-Oncology Approaches
Amgen Oncology is committed to investigating innovative approaches to fighting cancer, across both hematological malignancies and solid tumors.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Dr. Volker Heinemann, MD, PhD
Latest:
Dr. Volker Heinemann on the Addition of SIRT to Chemotherapy for mCRC
Volker Heinemann, MD, PhD, director of the Comprehensive Cancer Center at Ludwig Maximilian University of Munich, discusses how depth of response, which is highly correlated with overall survival, was improved for patients with metastatic colorectal cancer who added selective internal radiation therapy (SIRT) to chemotherapy.
Drew Moghanaki, MD, MPH
Latest:
Dr. Moghanaki on Remaining Questions Following the CheckMate-816 Trial in NSCLC
Drew Moghanaki, MD, MPH, discusses questions that still need to be addressed following the phase 3 CheckMate-816 trial of the neoadjuvant combination nivolumab plus chemotherapy in patients with non–small cell lung cancer.
Dungsa Chen PhD
Latest:
Phase II Clinical Trial of Intratumoral Dendritic Cells Injections and Neoadjuvant Radiotherapy in Resectable Soft Tissue Sarcomas
Neoadjuvant radiation with dendritic cell injections has the potential to be safe, effective, and immunogenic in high-grade soft tissue sarcoma and needs to be confirmed in randomized larger clinical trials.
Dustin M. Walters, MD
Latest:
Dr. Walters on the Best Approach to Treating Patients With Stage III Lung Cancer
Dustin M. Walters, MD, assistant professor, Thoracic and Cardiovascular Surgery, University of Virginia Health System, discusses the best approach to treating patients with stage III lung cancer.
E. David Crawford, MD, & Kyle O. Rove, MD
Latest:
Advanced Prostate Cancer: Therapeutic Sequencing, Outcomes, and Cost Implications
There is a dramatic revolution under way in the treatment of advanced-stage prostate cancer, which for many years consisted of systemic chemotherapy that offered only palliation of symptoms and no hope of improved survival.
E. David Crawford, MD, Neal D. Shore, MD
Latest:
Beyond PSA: A Summary Review of Predictive/Prognostic Biomarkers in Prostate Cancer
Although prostate cancer (PC) is the most common solid tumor malignancy among men in the Western Hemisphere, disease-specific mortality remains low, primarily due to optimized screening, diagnosis, and treatment.
E. Gabriela Chiorean, MD, SCCA
Latest:
Poised Potential With Zenocutuzumab in NRG1+ Pancreatic Cancer
E. Gabriela Chiorean, MD, of Fred Hutch Cancer Center, discusses the recent clinical data with zenocutuzumab in patients with NRG1 fusion–positive pancreatic cancer and the impact the approval of this agent could have on the landscape.
E. Roy Berger, MD, FACP
Latest:
A Riddle, Wrapped in a Mystery, Inside an Enigma
At last year's American Society of Clinical Oncology (ASCO) meeting, the official focus was on seeing personalized cancer medicine translated from a theoretical approach to a practical one. As you will see in this issue of Oncology & Biotech News, success is being realized on this front.